Irritable Bowel Syndrome Treatment Market 2020: Global Industry Exhibits Huge Growth by Top Key Players
The constantly increasing economic burden of IBS affects
work productivity and leads to an increase in healthcare costs. This, in turn,
has raised awareness about the disorder, thus, favoring the expansion of the
global market. In addition, the large-scale prevalence of anxiety and
depression is anticipated to catalyze the growth of the irritable bowel
syndrome treatment market over the assessment period.
According to Market Research Future (MRFR)’s new study, the
global irritable
bowel syndrome treatment market is projected to thrive at a CAGR of 7.58%
during the forecast period 2018 to 2023. The valuation of the global market has
been estimated to reach USD 2,988.6 Mn towards the end of 2023 from USD 1,890.9
Mn in 2017. It is presumed to scale new heights over the next few years owing
to the consolidation of a substantial patient population.
The key players are continually investing in drug development
for capitalizing on the rising patient pool. Furthermore, the collaborations
among the key players are supposed to have a positive influence on the
proliferation of the irritable bowel syndrome treatment market. On the flip
side, stringent regulations framed by governments and limited patient
satisfaction are predicted to hinder the proliferation of the market during the
assessment period.
Global Market for Irritable Bowel Syndrome Treatment –
Competitive Dashboard:
Some of the key players profiled in the report are Abbott,
Allergan Inc., Ardelyx Inc., Astellas Pharma, Inc., Ironwood Pharmaceuticals,
Lexicon Pharmaceuticals, Inc., Mallinckrodt, Nestle Health Science, Synergy
Pharmaceuticals Inc., and Valeant Pharmaceuticals International, Inc.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7044
Global Market for Irritable Bowel Syndrome Treatment –
Segmental analysis:
This MRFR report offers a detailed segmental analysis of the
global irritable bowel syndrome treatment market based on type, drug type, and
end-user. By type, the market has been segmented into IBS-C, IBS-D, and IBS-M.
Among these, IBS-D segment is currently dominating the global market and is
projected to retain its dominance in the upcoming years. Its valuation is
poised to reach USD 1790.6 Mn striking a CAGR of 8.31% over the assessment
period.
By drug type, the irritable bowel syndrome treatment market
has been segmented into lubiprostone, linaclotide, eluxadoline, rifaximin,
alosetron, and others. The linaclotide segment is expected to grow
significantly in the foreseeable future. It is anticipated to mark a relatively
higher CAGR of 7.95% through the projection period. The growth trajectory of
the segment is forecasted to be dictated by the increasing collaborations among
the key players.
By end-user, the market is segmented into hospitals,
clinics, research laboratories, and others. Among these, the hospital segment
accounts for the maximum share of the irritable bowel syndrome treatment market
and is presumed to thrive at a comparatively higher CAGR across the review
period. The factors that are likely to drive the expansion of the segment in
the forthcoming years include the rising number of hospitals, increasing demand
for affordable treatments, and growing patient population.
Regional Outlook:
The Global Irritable Bowel Syndrome Treatment Market, by
region, has been segmented into Americas, Europe, Asia Pacific, and the Middle
East & Africa. Americas is the largest market for irritable bowel syndrome
treatment. The regional market is likely to benefit from the rising awareness about
IBS, increasing patient pool, presence of a developed healthcare sector, rising
burden of IBS, etc. The valuation of the market is estimated to grow from USD
851.1 Mn in 2017 to USD 1,416.2 Mn by the end of 2023, striking a CAGR of 8.69%
through the assessment period. North America is poised to command a larger
share of the regional market than South America over the next few years.
Europe resonates promising potential for growth and is
prognosticated to accelerate revenue creation for market participants in the
forthcoming years. Factors such as rising research & development
expenditure, the presence of a huge patient population, growing demand for
treatment options are expected to catapult the irritable bowel syndrome
treatment market in the region on an upward trajectory.
The irritable bowel syndrome treatment market in Asia
Pacific is poised to witness significant growth in the upcoming years. The
rapid developments in the healthcare sector coupled with rising healthcare
expenditure is projected to provide an impetus to the market expansion.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/irritable-bowel-syndrome-treatment-market-7044
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment